Acute myeloid leukemia and additional hematological malignancies.

Malignancy Cell publishes a paper on ARIAD Pharmaceuticals’ Pan-BCR-ABL inhibitor ARIAD Pharmaceuticals, Inc. The publication describes for the very first time the chemical framework of AP24534 and its own activity against all known BCR-ABL mutants, like the T315I mutant that is resistant to presently marketed therapies for persistent myeloid leukemia . The paper provides a comprehensive description of the experience of AP24534 in a variety of established cell-based and animal types of CML online . AP24534 was uncovered by ARIAD researchers and is currently in a Phase 1 dose-escalating clinical trial in sufferers with refractory CML, acute myeloid leukemia and additional hematological malignancies.